Abstract 20032: Outpatient Exposure to Potentially Harmful Drugs in Patients With Heart Failure
Background: Several drugs have the potential to cause or decompensate heart failure (HF).
Objective: To evaluate the frequency of potentially harmful drug exposure after hospital discharge in patients with heart failure.
Methods: This was a retrospective analysis of Blue Cross Blue Shield of Texas (BCBSTX) claims data (2008-2013) which contains information for medical and pharmacy services. We included patients with at least one admission with a primary or secondary diagnosis for heart failure as defined by ICD-9 codes. We then analyzed all pharmaceutical claims for those patients as of day of discharge. Exposure to potentially harmful drugs (PHD) was defined as the use of non-steroidal anti-inflammatory agents (NSAIDS), Thiazolidinediones (TZD), Alpha-blockers (AB), Antiarrhythmic (AA) and non-dihydropyridine calcium channel blockers (non DPCCB) as recorded in pharmaceutical claims using AHFS Pharmacologic-Therapeutic Classification.
Results: A total of 35317 discharges with a primary or secondary diagnosis of heart failure were identified, of which we analyzed a subset of 13,926 discharges from a total of 9,784 patients who had pharmacy coverage through BCBSTX.
We found that of 5,730 (69%) had a prescription for at least one PHD after discharged. NSAIDS were the most common category 77% (4430) followed by AA 781(13.6%), non DPCCB 322 (5.6%), TZD 103 (1.8%) and AB 94 (1.6%). Most cases were recorded as new prescription claims with a relatively short interval between discharge and prescription. (Table 1)
Conclusion: In patients discharged from the hospital with a primary or secondary diagnosis of heart failure, exposure to potentially harmful drugs is not uncommon, especially NSAIDS. Further research to define the consequences of this exposure is needed.
Author Disclosures: P. Alvarez: None. C. Ganduglia: None. D. Putney: None. J.D. Estep: None.
- © 2015 by American Heart Association, Inc.